Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats

References

• Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernas H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large intestine. Molecular Pharmacology 2007; 4: 252–257
   PubMed Web of Science ®Google Scholar
• Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, De Waziers I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2, and CYP3 families in 22 different human tissues. Pharmacogenetics and Genomics 2007; 17: 731–742
   PubMed Web of Science ®Google Scholar
• Carillo BA, Beutel A, Mirandola DA, Vidonho AF, Jr, Furukawa LNS, Casarini D, Campo RR, Dolnikoff MS, Heimann JC, Bergamaschi CT. Differential sympathetic and angiotensinergic responses in rats submitted to low- or high-salt diet. Regulatory Peptides 2007; 140: 5–11
   PubMedGoogle Scholar
• Culm-Merdek KE, Von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clinical Pharmacology and Therapeutics 2006; 79: 243–254
   PubMed Web of Science ®Google Scholar
• Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 2001; 299: 825–831
   PubMed Web of Science ®Google Scholar
• Darbar D, Dell’Orto S, Mörike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clinical Pharmacology and Therapeutics 1997; 61: 292–300
   PubMed Web of Science ®Google Scholar
• Darbar D, Fromm MF, Dell’Orto S, Kim RB, Kroemer HK, Eichelbaum M, Roden DM. Modulation by dietary salt of verapamil disposition in humans. Circulation 1998; 98: 2702–2708
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky LS. Human extrahepatic cytochrome P450: function in xenobiotic metabolism and tissue selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual Review of Pharmacology and Toxicology 2003; 43: 149–173
   PubMed Web of Science ®Google Scholar
• Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology 2003; 95: 1297–1300
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clinical Pharmacology and Therapeutics 2007; 81: 362–370
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J, Weimar W, Van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics 2003; 74: 245–254
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences. USA 97 2000; 3473–3478
   Google Scholar
• Ito T, Asakura K, Tougou K, Fukuda T, Kubota R, Nonen S, Fujio Y, Azuma J. Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes. Molecular Pharmacology 2007; 72: 173–181
   PubMed Web of Science ®Google Scholar
• Kosuge K, Chuang AI, Uematsu S, Tan KP, Ohashi K, Ko BC, Ito S. Discovery of osmo-sensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5) molecular pharmacology 72 2007; 826–837
   Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001; 27: 383–391
   PubMed Web of Science ®Google Scholar
• Lam AK, Ko BC, Tam S, Morris R, yang JY, Chung SK, Chung SS. Osmotic response element-binding protein (OREBP) is an essential regulator of the urine concentrating mechanism. Journal of Biological Chemistry 2004; 279: 48048–48054
   PubMed Web of Science ®Google Scholar
• Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo WS, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. Journal Clinical Investigation 1997a; 99: 2545–2553
   PubMed Web of Science ®Google Scholar
• Lown KS, Mayo RR, Leichtman AB, Hsaio H, Turgeon K, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics 1997b; 62: 248–260
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug metabolism and Toxicology 2006; 2: 875–894
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 2004; 75: 13–33
   PubMed Web of Science ®Google Scholar
• Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metabolism and Disposition 2004; 32: 1008–1014
   PubMed Web of Science ®Google Scholar
• Morales MM, Capella MA, Sanches MV, Lopes AG, Guggino WB. Modulation of the mdr-1bgene in the kidney of rats subjected to dehydration or a high-salt diet. Pflugers Archiv 2000; 439: 356–362
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochrome P450. Lancet 2002; 360: 1155–1162
   PubMed Web of Science ®Google Scholar
• Ni XP, Humphreys MH. Prevention of salt-induced hypertension by an analog of γ-melanocyte-stimulating hormone in the rat. American Journal Hypertension 2007; 20: 862–865
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy KM, Karet FE. Salt handling and hypertension. Annual Review of Nutrition 2006; 26: 343–365
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 1552–1562
   PubMed Web of Science ®Google Scholar
• Reinehr R, Graf D, Fischer R, Schliess F, Haussinger D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Hepatology 2002; 36: 602–614
   PubMed Web of Science ®Google Scholar
• Reinehr R, Schliess F, Haussinger D. Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation. FASEB Journal 2003; 17: 731–733
   PubMed Web of Science ®Google Scholar
• Stiborová M, Borek-Dohalská L, Aimová D, Kotrbová V, Kukacková K, Janouchová K, Rupertová M, Ryslavá H, Hudecek J, Frei E. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes — similarity between human and rat systems. General Physiology and Biophysics 2006; 25: 245–261
   PubMed Web of Science ®Google Scholar
• Teixeira D, Sheth U, Valencia-Sanchez MA, Brengues M, Parker R. Processing bodies require RNA for assembly and contain nontranslating mRNAs. RNA 2005; 11: 371–382
   PubMed Web of Science ®Google Scholar
• Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. Current Topics in Medicinal Chemistry 2004; 4: 1399–1409
   PubMed Web of Science ®Google Scholar
• Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. American Journal of Human Genetics 2004; 75: 1059–1069
   PubMed Web of Science ®Google Scholar
• Titze J, Lang R, Ilies C, Schwind KH, Kirsch KA, Dietsch P, Luft FC, Hilgers KF. Osmotically inactive skin Na+ storage in rats. American Journal of Physiology Renal Physiology 2003; 285: F1108–F1117
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 1995; 13: 129–134
   PubMed Web of Science ®Google Scholar
• Woo SK, Lee SD, Kwon HM. TonEBP transcriptional activator in the cellular response to increased osmolality. Pflugers Archiv 2002; 444: 579–585
   PubMed Web of Science ®Google Scholar
• Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmaceutical Research 2005; 28: 249–268
   PubMed Web of Science ®Google Scholar